Medtronic: Q2 2018-19 EPS up 14%
(CercleFinance.com) - Medtronic has reported adjusted net earnings that are up 14% at 1.
66 billion dollars, or 1.22 euros per share, for sales that are up 6.1% at 7.5 billion dollars (+7.5% in organic terms).
"Our end markets are strong, and we are leading in most of the fastest growing markets in medical technology," said Omar Ishrak, the Chairman and CEO of the Dublin-based medical equipment supplier.
Over FY 2018-19, Medtronic maintains an adjusted EPS target range of between 5.10 dollars and 5.15 dollars, but has raised its forecast for organic sales growth to between 5% and 5.5%, versus 4.5% to 5% previously.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
66 billion dollars, or 1.22 euros per share, for sales that are up 6.1% at 7.5 billion dollars (+7.5% in organic terms).
"Our end markets are strong, and we are leading in most of the fastest growing markets in medical technology," said Omar Ishrak, the Chairman and CEO of the Dublin-based medical equipment supplier.
Over FY 2018-19, Medtronic maintains an adjusted EPS target range of between 5.10 dollars and 5.15 dollars, but has raised its forecast for organic sales growth to between 5% and 5.5%, versus 4.5% to 5% previously.
Copyright (c) 2018 CercleFinance.com. All rights reserved.